At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
deferasirox +2 moredrug
Likely dose
deferasirox 20 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·interventional·Posted Jan 9, 2007·Updated Oct 16, 2023
In Brief
A Phase 2 clinical trial evaluating deferasirox, Placebo, and 1 other intervention for Mucormycosis. Completed, enrolled 20 participants across 7 sites.
Detailed Summary
The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMucormycosis
CountriesUnited States
CollaboratorsGilead Sciences, Astellas Pharma Inc, Novartis
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartOct 2007
Primary CompletionDec 2009
Study CompletionDec 2010
TodayJul 2026
First PostedJan 9, 2007
Enrollment StartOct 1, 2007
Primary CompletionDec 1, 2009
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.5 years ago
Interventions
deferasiroxdrug
20 mg/kg enterally per day
Placebodrug
Liposomal amphotericin Bdrug